66 related articles for article (PubMed ID: 2788512)
1. Target cell-directed inactivation and IL-2-dependent reactivation of LAK cells.
Xiao J; Brahmi Z
Cell Immunol; 1989 Sep; 122(2):295-306. PubMed ID: 2788512
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets.
Chong AS; Aleksijevic A; Scuderi P; Hersh EM; Grimes WJ
Cancer Immunol Immunother; 1989; 29(4):270-8. PubMed ID: 2502310
[TBL] [Abstract][Full Text] [Related]
3. The heterogeneity of target recognition by lymphokine-activated killer precursor cells.
Ibayashi Y; Gray JD; Golub SH; Daibo M; Yamaki T; Kawahara T; Kubota T; Hashi K
Jpn J Cancer Res; 1990 Sep; 81(9):927-35. PubMed ID: 2121694
[TBL] [Abstract][Full Text] [Related]
4. Bacterial superantigens as anti-tumour agents: induction of tumour cytotoxicity in human lymphocytes by staphylococcal enterotoxin A.
Lando PA; Hedlund G; Dohlsten M; Kalland T
Cancer Immunol Immunother; 1991; 33(4):231-7. PubMed ID: 2059967
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor.
Nagarkatti M; Nagarkatti PS; Kaplan AM
Cancer Immunol Immunother; 1988; 27(1):38-46. PubMed ID: 3260820
[TBL] [Abstract][Full Text] [Related]
6. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.
Liu Z; Smyth FE; Renner C; Lee FT; Oosterwijk E; Scott AM
Cancer Immunol Immunother; 2002 May; 51(3):171-7. PubMed ID: 11941456
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of in vitro LAK generation by OK-432.
Yagita M; Grimm EA
Cancer Immunol Immunother; 1986; 23(3):207-13. PubMed ID: 3491681
[TBL] [Abstract][Full Text] [Related]
8. Effects of cryopreservation on effector cells for antibody dependent cell-mediated cytotoxicity (ADCC) and natural killer (NK) cell activity in (51)Cr-release and CD107a assays.
Mata MM; Mahmood F; Sowell RT; Baum LL
J Immunol Methods; 2014 Apr; 406():1-9. PubMed ID: 24561308
[TBL] [Abstract][Full Text] [Related]
9. Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a)) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice.
Watanabe M; Kubota T; Kitajima M; Hakomori S
Cancer Immunol Immunother; 1993 Sep; 37(4):245-50. PubMed ID: 8348564
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro.
McVicar DW; Merchant RE; Merchant LH; Young HF
Cancer Immunol Immunother; 1989; 29(3):211-8. PubMed ID: 2499421
[TBL] [Abstract][Full Text] [Related]
11. Large-scale preparation of adherent lymphokine-activated killer (A-LAK) cells for adoptive immunotherapy in man.
Melder RJ; Rosenfeld CS; Herberman RB; Whiteside TL
Cancer Immunol Immunother; 1989; 29(1):67-73. PubMed ID: 2785002
[TBL] [Abstract][Full Text] [Related]
12. Modification of natural killer activity of lymphocytes infiltrating human lung cancers.
Anderson TM; Ibayashi Y; Holmes EC; Golub SH
Cancer Immunol Immunother; 1987; 25(1):65-8. PubMed ID: 3109739
[TBL] [Abstract][Full Text] [Related]
13. Role of proliferation in LAK cell development.
Ramsdell FJ; Shau H; Golub SH
Cancer Immunol Immunother; 1988; 26(2):139-44. PubMed ID: 3129192
[TBL] [Abstract][Full Text] [Related]
14. TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.
Grimm EA; Crump WL; Durett A; Hester JP; Lagoo-Deenadalayan S; Owen-Schaub LB
Cancer Immunol Immunother; 1988; 27(1):53-8. PubMed ID: 3260821
[TBL] [Abstract][Full Text] [Related]
15. Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-alpha (Wellferon).
Pawelec G; Schneider E; Ehninger G; Rehbein A; Schmidt H
Cancer Immunol Immunother; 1989; 29(1):63-6. PubMed ID: 2785001
[TBL] [Abstract][Full Text] [Related]
16. Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.
Primus FJ; Pendurthi TK; Hutzell P; Kashmiri S; Slavin DC; Callahan R; Schlom J
Cancer Immunol Immunother; 1990; 31(6):349-57. PubMed ID: 2386980
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alpha.
Vuist WM; Visseren MJ; Otsen M; Bos K; Vyth-Dreese FA; Figdor CG; Melief CJ; Hekman A
Cancer Immunol Immunother; 1993; 36(3):163-70. PubMed ID: 8439976
[TBL] [Abstract][Full Text] [Related]
18. Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2.
Eisenthal A
Cancer Immunol Immunother; 1990; 31(6):342-8. PubMed ID: 2386979
[TBL] [Abstract][Full Text] [Related]
19. Effects of phenytoin on cell-mediated immunity.
Okamoto Y; Shimizu K; Tamura K; Miyao Y; Yamada M; Tsuda N; Matsui Y; Mogami H
Cancer Immunol Immunother; 1988; 26(2):176-9. PubMed ID: 3258793
[TBL] [Abstract][Full Text] [Related]
20. Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy.
Navarrete-Galvan L; Guglielmo M; Cruz Amaya J; Smith-Gagen J; Lombardi VC; Merica R; Hudig D
J Transl Med; 2022 Apr; 20(1):151. PubMed ID: 35366943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
